Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 4/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 9/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 9/20 | 0.35 |
| ▸ | ASH1L | Q9NR48 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.33 |
| ▸ | POLQ | O75417 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14184123 | 0.87 | TUBB4A (0.39) | HSD11B1HSP90AA1HSP90AB1ASH1LPOLQ | |
| SCHEMBL12694054 | 0.84 | HSD11B1 (0.36) | HSD11B1HSP90AA1HSP90AB1ASH1LKDM4E | |
| SCHEMBL9925250 | 0.82 | GOT1 (0.36) | HSP90AA1ASH1LGAAMAPT | |
| SCHEMBL2596691 | 0.81 | DAO (0.33) | HSP90AA1KDM4EGAAMAPTLMNA | |
| SCHEMBL12180120 | 0.77 | AOC3 (0.38) | KDM4EGAAMAPTLMNA | |
| SCHEMBL1148300 | 0.75 | ASH1L (0.36) | HSD11B1HSP90AA1ASH1LKDM4EGAA | |
| SCHEMBL12908734 | 0.75 | PDE4D (0.37) | HSP90AA1KDM4EGAAMAPTLMNA | |
| SCHEMBL421350 | 0.74 | KDM4E (0.35) | HSP90AA1HSP90AB1KDM4EGAAMAPT | |
| SCHEMBL931405 | 0.74 | KMT2A (0.48) | KDM4EMAPTLMNA | |
| SCHEMBL444954 | 0.73 | HSP90AA1 (0.39) | HSP90AA1HSP90AB1KDM4EGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 160 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150150851-A1 | FORMULATION AND DOSING OF HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-04 | — | — | US | claimed |
| EP-2035396-B1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2014-05-14 | — | — | EP | claimed |
| US-20130116253-A1 | Novel HSP90 Inhibitor | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2013-05-09 | — | — | US | claimed |
| US-20130116252-A1 | Novel HSP90 Inhibitor | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2013-05-09 | — | — | US | claimed |
| US-8053456-B2 | Triazole compounds that modulate Hsp90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2011-11-08 | — | — | US | claimed |
| US-20080176840-A1 | e.g. 4-(4-(6-(N-(2-methoxyethyl)-N-methylamino)pyridin-3-yl)-5-hydroxy-4H-1,2,4-triazol-3-yl)-6-isopropylbenzene-1,3-diol; Heat Shock Protein 90 (HSP90) modulator; antiproliferative, anticarcinogenic, antiinflammatory agent; angiogenesis inhibition, infections | SYNTA PHARMACEUTICALS CORP | 2008-07-24 | — | — | US | claimed |
| US-20180221345-A1 | COMBINATION THERAPY OF HSP90 INHIBITORS WITH PLATINUM-CONTAINING AGENTS | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2018-08-09 | — | — | US | disclosed |
| US-20180221345-A1 | COMBINATION THERAPY OF HSP90 INHIBITORS WITH PLATINUM-CONTAINING AGENTS | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2018-08-09 | — | — | US | disclosed |
| US-20180221345-A1 | COMBINATION THERAPY OF HSP90 INHIBITORS WITH PLATINUM-CONTAINING AGENTS | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2018-08-09 | — | — | US | disclosed |
| US-20170340652-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH CHK INHIBITORS | SYNTA PHARMACEUTICALS CORP. | 2017-11-30 | — | — | US | disclosed |
| US-20170340652-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH CHK INHIBITORS | SYNTA PHARMACEUTICALS CORP. | 2017-11-30 | — | — | US | disclosed |
| US-20170340652-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH CHK INHIBITORS | SYNTA PHARMACEUTICALS CORP. | 2017-11-30 | — | — | US | disclosed |
| US-9439899-B2 | Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors | SYNTA PHARMACEUTICALS CORP. (US) | 2016-09-13 | — | — | US | disclosed |
| US-20080027047-A1 | Compounds that modulate HSP90 activity and methods for identifying same | SYNTA PHARMACEUTICALS CORP | 2008-01-31 | — | — | US | disclosed |
| US-20080027047-A1 | Compounds that modulate HSP90 activity and methods for identifying same | SYNTA PHARMACEUTICALS CORP | 2008-01-31 | — | — | US | disclosed |
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20080004266-A1 | Method for treating proliferative disorders associated with protooncogene products | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20080004266-A1 | Method for treating proliferative disorders associated with protooncogene products | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2008-01-03 | — | — | US | disclosed |
| US-20060167070-A1 | heat shock protein 90 inhibitors such as 3-(2-Hydroxyphenyl)-4-(naphthalen-1-yl)-5-mercapto-triazole, used for for preventing or treating hyperproliferative disorders, such as cancer | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180221345-A1 | COMBINATION THERAPY OF HSP90 INHIBITORS WITH PLATINUM-CONTAINING AGENTS | HSP90AB1, HSP90AA1, HSP90B1 | HSD11B1 1185/4885HSP90AA1 2/4885HSP90AB1 1/4885 |
| US-20130116252-A1 | Novel HSP90 Inhibitor | HSP90AB1, HSP90AB2P, HSP90B1 | HSD11B1 428/4885HSP90AA1 4/4885HSP90AB1 1/4885 |
| US-20130116253-A1 | Novel HSP90 Inhibitor | HSP90AB1, HSP90AB2P, HSP90B1 | HSD11B1 428/4885HSP90AA1 4/4885HSP90AB1 1/4885 |
| US-20170340652-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH CHK INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | HSD11B1 1108/4885HSP90AA1 2/4885HSP90AB1 1/4885 |
| US-20080004276-A1 | Method for treating non-hodgkin's lymphoma | HSP90AB1, HSP90AB2P, HSP90B1 | HSD11B1 787/4885HSP90AA1 4/4885HSP90AB1 1/4885 |
| US-20080176840-A1 | e.g. 4-(4-(6-(N-(2-methoxyethyl)-N-methylamino)pyridin-3-yl)-5-hydroxy-4H-1,2,4-triazol-3-yl)-6-isopropylbenzene-1,3-diol; Heat Shock Protein 90 (HSP90) modulator; antiproliferative, anticarcinogenic, antiinflammatory agent; angiogenesis inhibition, infections | HSP90AB1, HSP90AB2P, HSP90B1 | HSD11B1 1143/4885HSP90AA1 4/4885HSP90AB1 1/4885 |
| US-20150150851-A1 | FORMULATION AND DOSING OF HSP90 INHIBITORY COMPOUNDS | HSP90AB1, HSP90AA1, HSP90AB2P | HSD11B1 464/4885HSP90AA1 2/4885HSP90AB1 1/4885 |
| US-20080027047-A1 | Compounds that modulate HSP90 activity and methods for identifying same | HSP90AB1, HSP90B1, CDC37 | HSD11B1 1444/4885HSP90AA1 4/4885HSP90AB1 1/4885 |
| US-20080004266-A1 | Method for treating proliferative disorders associated with protooncogene products | HSP90AB1, HSP90AB2P, HSP90AA1 | HSD11B1 3353/4885HSP90AA1 3/4885HSP90AB1 1/4885 |
| US-20060167070-A1 | heat shock protein 90 inhibitors such as 3-(2-Hydroxyphenyl)-4-(naphthalen-1-yl)-5-mercapto-triazole, used for for preventing or treating hyperproliferative disorders, such as cancer | HSP90AB1, HSP90AB2P, HSP90AA1 | HSD11B1 962/4885HSP90AA1 3/4885HSP90AB1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.